Biotech is one of the most exciting and most demanding industries in the world. It's where cutting-edge science meets real-world medicine, where small teams with bold ideas chase cures that could change millions of lives.
And yet, despite the massive growth of the sector over the past two decades, a surprisingly large number of people, including some who work adjacent to it, aren't entirely sure what separates a biotech company from a pharmaceutical company, how these businesses actually operate, or what it takes to survive the journey from scientific hypothesis to approved drug.
If you're asking "what is a biotech company?", you're in good company. This guide will walk you through everything you need to know: what biotech companies are, how they work, what regulatory frameworks govern them, and what operational infrastructure they need to succeed.
Defining a Biotech Company
At its core, a biotechnology company is a business that uses living organisms, biological systems, or their derivatives to develop commercial products. That definition is broad by design. Biotechnology touches agriculture, environmental science, industrial manufacturing, and more. But for the purposes of this article, we're focusing on what most people mean when they say "biotech": companies working in human health, developing drugs, therapies, diagnostics, and medical technologies rooted in biology.
The outputs of health-focused biotech companies include biologics (drugs derived from biological sources like proteins or cells), gene therapies, cell therapies, monoclonal antibodies, vaccines, and RNA-based medicines. These aren't the small-molecule chemical compounds of traditional pharmaceutical development. They are complex, living-system-derived products that require highly specialized development processes and strict regulatory oversight.
One of the most important things to understand about biotech companies is that the industry skews small. Today, over 70% of active drug trials are sponsored not by large, established pharmaceutical giants, but by smaller, fast-moving teams, often startups or mid-sized companies that are still pre-revenue, pre-approval, and operating on investor capital. These teams are lean, often cross-functional, and working under enormous time and compliance pressure. That context matters a great deal when you start to understand how biotech companies are structured and what tools they need to succeed.
Biotech vs. Pharma: What's the Difference?
The distinction between biotech and pharma is real, but it's getting harder to draw. Here's the traditional breakdown:
Pharmaceutical companies develop drugs through chemical synthesis. They tend to be large, established businesses with broad commercial portfolios, multiple approved products, and the internal resources to fund late-stage development and commercialization themselves. Think of the major multinational companies that have been household names for decades.
Biotechnology companies develop products using biological systems: recombinant proteins, living cells, gene editing tools, and similar techniques. They tend to be smaller, more specialized, and often focused on a single therapeutic area or even a single compound. Many are pre-commercial, meaning they've never sold a product. Their value is in their pipeline, their intellectual property, and the promise of what they're building.
In practice, the line between these two categories has blurred significantly. Large pharma companies have spent the last two decades acquiring biotech companies to replenish their pipelines, and many of those acquired biotechs had already grown large enough that the "small startup" label no longer fit. Today, companies like Amgen and Biogen, which started as pure-play biotechs, are effectively pharmaceutical companies by any practical measure.
What matters most for the purpose of this guide is understanding what early-to-mid-stage biotech companies look like operationally. These are teams that are running clinical trials, managing regulatory submissions, building quality systems, and trying to stay compliant, often with lean headcount and limited resources. Their challenges are distinct, and the tools they need are distinct too.
How Does a Biotech Company Work?
Bringing a biotech product to market is a long, expensive, and highly regulated process. Understanding that process is key to understanding why biotech companies are structured the way they are and why compliance infrastructure is so critical.
Discovery and Research
Everything begins in the lab. Scientists identify a biological target, a protein, a gene, a cellular pathway, that plays a role in a disease. They then develop a potential therapy designed to interact with that target in a therapeutic way. This phase is largely experimental, driven by academic research partnerships, internal R&D teams, or licensing agreements with universities. Timelines are long and success rates are low.
Preclinical Development
Before any therapy can be tested in humans, it has to be tested in the lab and in animal models. Preclinical studies generate the safety and efficacy data required to justify moving to human trials. This phase also involves significant documentation, including study reports, toxicology data, and pharmacology data, that will eventually be packaged into an Investigational New Drug (IND) application submitted to the FDA (or its equivalent in other regions).
Clinical Trials (Phase I, II, and III)
If the FDA accepts the IND application, the company can begin testing in humans. Clinical trials happen in three phases, each progressively larger and more expensive:
- Phase I tests the therapy in a small number of healthy volunteers or patients primarily for safety and dosing.
- Phase II expands to a larger patient population to begin assessing efficacy alongside safety.
- Phase III involves hundreds to thousands of patients across multiple sites and is designed to generate the robust efficacy and safety data required for regulatory approval.
This phase generates enormous volumes of documentation, including clinical protocols, investigator agreements, site files, patient records, monitoring reports, and safety data. Managing this documentation in a compliant way is one of the central operational challenges of clinical-stage biotech.
Regulatory Submission
If Phase III results are positive, the company compiles all of its clinical, preclinical, and manufacturing data into a regulatory submission, typically a New Drug Application (NDA) or Biologics License Application (BLA) in the US, or a Marketing Authorization Application (MAA) in Europe. These are massive, complex documents submitted in electronic common technical document (eCTD) format.
Approval and Commercialization
Regulatory agencies review the submission and either approve, request additional information, or reject the application. If approved, the company can begin selling the product, but now faces the challenge of manufacturing at scale and standing up commercial operations.
Post-Market Surveillance
Approval isn't the end of the regulatory relationship. Companies must continue monitoring the safety of approved products, reporting adverse events, and maintaining compliance with ongoing regulatory requirements.
Most biotech companies never make it through all six stages. The failure rate in clinical development is high, which makes process efficiency and documentation quality not just operational concerns, but strategic ones. A compliance failure at any stage can set a program back by months or years.
How Biotech Companies Are Structured
Because most biotech companies are relatively small, they tend to be structured around cross-functional teams rather than large departmental hierarchies. Common functional areas include:
Research and Development (R&D): The scientific engine of the company. R&D teams design and run experiments, generate data, and develop the product candidates that the rest of the company is built around.
Clinical Operations: Manages the execution of clinical trials, including site selection, patient enrollment, monitoring, data collection, and closeout. Often works closely with CROs (Contract Research Organizations), which are external service providers that handle many of the day-to-day logistics of running a trial.
Regulatory Affairs: Responsible for managing the company's relationship with regulatory agencies. Regulatory teams prepare submissions, respond to agency requests, track commitments, and ensure that the company's operations stay in compliance with applicable regulations.
Quality Assurance (QA): Owns the quality management system. QA teams write and approve SOPs, manage quality events like deviations and CAPAs, conduct internal audits, and oversee vendor qualification. They are often the people most directly responsible for ensuring the company can survive an inspection.
Medical Affairs and Pharmacovigilance: More relevant in later-stage companies, these functions manage scientific communication and post-market safety monitoring.
Finance and Business Development: Manages capital, investor relations, partnerships, and licensing deals.
In an early-stage biotech, one person might wear several of these hats simultaneously. As the company grows through clinical stages, each function typically becomes more specialized and staffed accordingly.
Regulatory Requirements for Biotech Companies
Regulatory compliance is not optional in biotech. It is the cost of doing business. The regulatory frameworks governing biotech companies are extensive, and navigating them requires expertise, attention to detail, and the right systems.
In the United States, the FDA is the primary regulatory authority. The key compliance framework for biotech companies includes:
21 CFR Part 11: This regulation governs electronic records and electronic signatures. It establishes the requirements that computer systems must meet in order for their records to be considered trustworthy and equivalent to paper records. If your team is storing documents, approving SOPs, or managing clinical data in any electronic system, Part 11 applies.
GCP (Good Clinical Practice): International standards for the design, conduct, and documentation of clinical trials. GCP compliance ensures that trial results are credible and that the rights and safety of trial participants are protected.
GxP Standards Broadly: GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) apply to lab studies and manufacturing, respectively.
In Europe, the European Medicines Agency (EMA) governs the regulatory environment. EU Annex 11 is the European equivalent of 21 CFR Part 11. The ICH (International Council for Harmonisation) publishes guidelines that are broadly adopted across multiple major regulatory regions, providing a degree of global standardization.
What does compliance look like in practice? It means having controlled document management, audit trails, electronic signatures, version control, and validated systems, all before you ever walk into an inspection. It means your Trial Master File (TMF) is complete and current. It means your quality system is documented, followed, and monitored. It means your regulatory submissions are tracked and your agency commitments are never missed.
The consequences of non-compliance range from inspection findings and warning letters to clinical holds that pause an entire trial. For a company that may be burning through investor capital with no product revenue, these setbacks can be existential.
The Document and Data Challenge in Biotech
Here's the operational reality that most people outside of biotech don't appreciate: the paperwork is staggering.
A single Phase III clinical trial can generate tens of thousands of individual documents, including protocols, amendments, informed consent forms, site agreements, investigator CVs, monitoring visit reports, lab certifications, and safety reports. Each of those documents has a lifecycle: it's created, reviewed, revised, approved, distributed, and archived. Each step in that lifecycle must be documented and traceable.
In the early stages of a trial, it's common to see teams managing these documents with whatever tools are available, such as shared drives, SharePoint, email threads, and spreadsheets tracking document status. These solutions feel manageable at first. They stop feeling manageable very quickly.
The problem isn't just organizational. It's regulatory. The FDA has stated clearly that if a document was born electronic, it needs to stay electronic and traceable. Band-aid solutions like shared drives and email don't provide audit trails, don't enforce version control, don't support compliant electronic signatures, and are not designed to demonstrate an unbroken chain of custody. They expose your study, and all the work, money, and patient participation that went into it, to inspection and audit risk.
This is why purpose-built systems matter. A compliant Document Management System (DMS) doesn't just organize your files. It enforces your workflows, maintains your audit trail, controls your access permissions, and validates itself so you don't have to. An Electronic Trial Master File (eTMF) system built on the TMF Reference Model gives you real-time visibility into completeness and keeps your clinical documentation inspection-ready at all times.
What Tools Do Biotech Companies Use?
As biotech companies move through clinical stages, they typically build out a stack of purpose-built compliance and operations tools. The core systems include:
Document Management System (DMS): The foundation. A DMS provides a central, compliant repository for all controlled documents, including SOPs, policies, work instructions, and clinical protocols. Key features include version control, workflow automation, Part 11-compliant e-signatures, role-based access controls, and audit trails. A good DMS should integrate seamlessly with tools like Microsoft Word for collaborative authoring.
Electronic Trial Master File (eTMF): Specifically designed for clinical trial documentation. A proper eTMF is built on the TMF Reference Model, provides smart document placeholders, supports TMF completeness reporting, and keeps your trial documentation organized and inspection-ready from study startup through closeout and long-term storage.
Quality Management System (QMS): The operational backbone of the quality function. A QMS manages SOP authoring and approval, quality events (deviations, CAPAs), vendor qualification and audits, training records and curricula, and regulatory reporting. It should enforce consistent naming conventions, link training records directly to approved SOPs, and give quality leaders real-time visibility into the organization's quality posture.
Regulatory Information Management (RIM): The system of record for the regulatory affairs function. A RIM system manages submission planning and tracking, agency correspondence, health authority commitments, dossier management, and eCTD viewing. For companies filing in multiple regions, including the FDA, EMA, Health Canada, and MHRA, a RIM system is what keeps everything organized and on track.
For a long time, these four systems existed as separate products from separate vendors, requiring complex integrations and creating inevitable data silos. Today, modern platforms like Kivo combine all four into a single, unified workspace, purpose-built for the compliance requirements of life sciences teams, starting at $1,800/month with all-inclusive pricing and no hidden validation, support, or maintenance fees. Implementation takes weeks, not months.
The difference between a legacy system that takes 6 to 12 months to implement and a modern platform that's live in two weeks isn't just about convenience. For a clinical-stage biotech running against the clock, it's a strategic advantage.
Starting a Biotech Company: What You Need to Know
If you're in the early stages of building a biotech company, or advising one, here are the operational and compliance considerations that tend to get underestimated:
Build compliance infrastructure early. The temptation is to treat compliance as something you "get to" once you have data. Don't. Retrofitting compliance onto a clinical program mid-stream is painful, expensive, and risky. The systems, SOPs, and processes you put in place early set the foundation for everything that follows. Regulatory agencies want to see that quality was baked in from the beginning, not bolted on.
Choose your tools deliberately. The spreadsheets and shared drives that work in a two-person startup will not scale to a multi-site Phase II trial. Choose systems that are validated, Part 11 compliant, and designed for the regulated environment you're operating in. Your future regulatory affairs team and your future auditors will thank you.
Invest in regulatory expertise early. Regulatory strategy is not something you figure out after you have data. Engage with the FDA as early as possible. Consider pre-IND meetings. Build relationships with regulatory consultants or hire experienced regulatory affairs staff before you think you need them.
Understand the funding landscape. Most biotech companies are funded in stages that correspond roughly to clinical milestones. Seed and Series A rounds typically fund preclinical and early Phase I work. Series B and C are used to power Phase II and III. Understanding this cadence helps you plan your operational investments accordingly.
Leverage CRO relationships strategically. Most early-stage biotechs don't have the internal staff to run a clinical trial entirely on their own. CROs provide clinical operations expertise and infrastructure. But the sponsor, the biotech company, retains regulatory responsibility for the trial. That means your internal systems need to interface effectively with your CRO's systems, and your TMF needs to capture documentation from both sides.
The Future of Biotech
The biotech industry is evolving faster than at any point in its history. Several forces are reshaping what's possible:
AI-assisted drug discovery is dramatically compressing the timeline from target identification to lead compound. Companies are now using machine learning to design molecules, predict toxicity, and identify patient populations, work that previously took years.
Gene editing and cell therapy are moving from experimental to mainstream. CRISPR-based therapies and CAR-T cell treatments are already approved for certain indications, and the pipeline behind them is deep.
mRNA technology, validated publicly by COVID-19 vaccines, has opened new possibilities for therapeutic development across oncology, infectious disease, and rare disease.
Personalized medicine is shifting the paradigm from population-level treatment to individualized therapy based on genetic, biomarker, and lifestyle data.
Through all of this, one thing remains constant: regulatory agencies expect rigorous documentation, validated systems, and auditable processes. The tools and science are evolving. The compliance expectations are not.
Conclusion
Biotech companies sit at one of the most important intersections in modern science, where biological discovery meets the potential to change human health. They are complex organizations operating in a highly regulated environment, often with lean teams and significant time pressure.
Understanding what a biotech company is means understanding not just the science, but the operations behind the science: the clinical trial processes, the regulatory frameworks, the quality systems, and the document management infrastructure that makes it possible to actually get a drug approved and into patients' hands.
The companies that succeed aren't just the ones with the best science. They're the ones that combine scientific excellence with operational discipline, teams that know how to stay compliant, move quickly, and build the kind of documentation record that will hold up to scrutiny from the FDA, EMA, and every other agency that stands between discovery and approval.
If you're building that kind of team and looking for tools designed specifically for the compliance demands of life sciences, Kivo offers an integrated platform, DMS, eTMF, QMS, and RIM, built for emerging biotech and pharma companies. Affordable, validated, and ready in weeks. Get a demo to see what's possible.
